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A B S T R A C T
Despite transferrin being the main circulating carrier of iron in body ﬂuids, and iron overload conditions being
known to worsen stroke outcome through reactive oxygen species (ROS)-induced damage, the contribution of
blood transferrin saturation (TSAT) to stroke brain damage is unknown. The objective of this study was to obtain
evidence on whether TSAT determines the impact of experimental ischemic stroke on brain damage and whether
iron-free transferrin (apotransferrin, ATf)-induced reduction of TSAT is neuroprotective. We found that ex-
perimental ischemic stroke promoted an early extravasation of circulating iron-loaded transferrin (holo-
transferrin, HTf) to the ischemic brain parenchyma. In vitro, HTf was found to boost ROS production and to be
harmful to primary neuronal cultures exposed to oxygen and glucose deprivation. In stroked rats, whereas
increasing TSAT with exogenous HTf was detrimental, administration of exogenous ATf and the subsequent
reduction of TSAT was neuroprotective. Mechanistically, ATf did not prevent extravasation of HTf to the brain
parenchyma in rats exposed to ischemic stroke. However, ATf in vitro reduced NMDA-induced neuronal uptake
of HTf and also both the NMDA-mediated lipid peroxidation derived 4-HNE and the resulting neuronal death
without altering Ca2+-calcineurin signaling downstream the NMDA receptor. Removal of transferrin from the
culture media or blockade of transferrin receptors reduced neuronal death. Together, our data establish that
blood TSAT exerts a critical role in experimental stroke-induced brain damage. In addition, our ﬁndings suggest
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T
that the protective eﬀect of ATf at the neuronal level resides in preventing NMDA-induced HTf uptake and ROS
production, which in turn reduces neuronal damage.
1. Introduction
Stroke is a life-threatening disease that causes high rates of per-
manent disability subsequent to neuronal loss. Neurons die as a result of
interrelated processes that include glutamate excitotoxicity as a pri-
mary contributor, inﬂammation, and excess of free radical production.
The hydroxyl radical, the most harmful of the free radicals, is generated
through reactions catalyzed by iron [1,2], and several clinical and
preclinical studies indicate that a previous systemic iron overload
condition increases brain damage induced by ischemia [3–8].
The brain is physiologically sheltered from ﬂuctuations of systemic
iron, even under experimentally-induced systemic iron overload con-
ditions [4,9]. However, in the ischemic brain, the detrimental eﬀect of
iron overload might result from systemic iron pools reaching the brain
parenchyma. An important pool of systemic iron is known to circulate
in the bloodstream bound tightly, but reversibly, to transferrin (Tf) for
its transport, distribution and delivery to cells and tissues. Transferrin is
present in the blood in diﬀerent iron-bound forms: devoid of iron
(apotransferrin, ATf), as monoferric Tf, or as diferric Tf (holo-
transferrin, HTf). The relative amount of iron-free and iron-loaded Tf in
blood is given in terms of the % Tf saturation (TSAT), an index that
shows large diﬀerences among individuals in both diseased and healthy
human cohorts [10–12]. On average, 30% of Tf in blood is saturated
with iron, leaving a large amount of Tf sites available to bind iron, and
leaving virtually no potentially toxic free iron in blood [13].
Cells obtain iron by receptor-mediated endocytosis of HTf through
the speciﬁc interaction with the cell membrane transferrin receptor
(TfR) and the classical endosome recycling pathway [14]. In brain ca-
pillaries this classical pathway co-exists with an apical-to-basolateral
transcytosis of TfR ligands [15,16] through the endothelial cells from
blood into the brain parenchyma [17]. Since TfR binds HTf more avidly
than ATf (30-fold at physiological pH) [18,19], the circulating HTf:ATf
ratio might be crucial to determine the uptake of circulating HTf
through endothelial cells and into neurons, both cells types known to
have membrane TfR.
To date, neither the eﬀect of stroke on brain Tf uptake, nor the eﬀect
of TSAT on stroke-induced excitotoxic damage, nor the eﬀect of HTf on
OGD-induced neuronal reactive oxygen species (ROS) production or
neuronal death have been addressed. Nonetheless, under excitotoxic
conditions in vitro, it has been reported that cultured neurons or PC12
cells show an increased uptake of iron [20,21] and, noteworthy, Cheah
et al. also show that glutamatergic-driven iron import by neurons is
due, at least partially, to the uptake of iron bound to Tf [20].
The present study demonstrates an unreported role of transferrin
and TSAT on the infarct size and neurological outcome in rat models of
stroke that might have important clinical implications. This study
provides the rationale, the mechanism, and the proof of concept of the
beneﬁcial eﬀect of apotransferrin in stroke.
2. Materials and methods
2.1. Rat models of ischemic stroke by middle cerebral artery occlusion
(MCAO)
Diﬀerent human ischemic stroke conditions were reproduced in
three models of MCAO in adult male rats: (a) cortical infarct through
permanent MCAO (pMCAO) by ligature [22] in Sprague-Dawley rats
(250–270 g, Harlan Laboratories), (b) cortical infarct through transient
MCAO (tMCAO) (60 min) by ligature [22] in Sprague-Dawley rats
(250–270 g, Harlan Laboratories), and (c) cortical+subcortical infarct
through tMCAO by intraluminal thread (90 min) [23] in either 1/
Sprague-Dawley rats (320–360 g, Animal Breeding Facilities of the
Santiago de Compostela University, ABF-SCU) in the magnetic re-
sonance imaging (MRI) study, or 2/ Wistar rats (300–350 g, Charles
River Laboratories, [24]) for extravasation and 2,3,5-triphenyl-tetra-
zolium chloride (TTC)-based infarct assessment studies. Rats with a
drop< 50% in laser-doppler ﬂowmetry during the occlusion or un-
successfully reperfused were not allocated to the experimental groups.
Animals were randomly allocated to a treatment that had been con-
cealed by a code, and the outcome was also assessed blinded. The
thromboembolic stroke and reperfusion model was performed using
C57 mice (around 22 g) at the European Stroke Research Platform
(ESRP) by the group that ﬁrst described the model [25]. Details of this
model are described in that paper.
2.2. Treatments
Apotransferrin (Sigma-Aldrich) was prepared as a 50 mg/ml solu-
tion, according to the solubility data from the provider. Adult male rats
weighing an average of 250 g were administered 200 mg/kg apo-
transferrin, 4 ml/kg i.v. in a single bolus injection (around 1 ml/rat);
this is below the recommended volume of 5 ml/kg for an i.v. single
bolus injection. Administration of 300 mg/kg apotransferrin or un-
labelled HTf (250 mg/kg hHTf) in the High TSAT group required an i.v.
slow infusion. ATf was administered at reperfusion time or 1 h after a
permanent MCAO, whereas unlabelled HTf was administered before the
onset of surgical procedures.
2.3. MRI
MRI was performed on a 9.4 T Bruker Biospec (Bruker Biospin) with
20 cm-wide gradients’ insert of 440 mT/m. Apparent diﬀusion coeﬃ-
cient (ADC) maps were constructed by a mono-exponential pixel-by-
pixel ﬁtting of 7 echo planar diﬀusion-weighted images (EPI-DWI) ac-
quired with b values of 0, 100, 300, 600, 800, 1000 and 1400 s/mm2,
echo time = 30 ms, repetition time = 4 s, and 150 µm isotropic re-
solution (slice thickness = 1 mm). Perfusion-weighted images (PWI)
were acquired using an EPI-FAIR sequence, with echo time = 24 ms,
repetition time = 10 s, 22 inversion times ranging 30–2300 ms, (se-
lective) inversion slab = 4 mm, and 300 µm isotropic resolution (slice
thickness of 2 mm).
2.4. Biochemical assessment of infarct volume
Fresh brains were cut into coronal 2 mm-thick slices and stained
with 1% TTC in PBS at 37º C for 15 min. Cryopreserved paraf-
ormaldehyde-ﬁxed mice brains were cut into 15 µm slices, collected
onto poly-L-lysine-coated glass slides, and stained with cresyl violet
following the procedure described by Türeyen et al. [26] with minor
modiﬁcations. Infarct and hemisphere volumes were determined using
ImageJ (NIH, USA) and total infarct volume was corrected for brain
edema.
2.5. Neurological assessment
Each rat underwent a battery of neurological tests before pMCAO
and 24 h later. We used in-lab modiﬁcations of the whiskers’ stimula-
tion response, elevated prehensile traction, corner turn, adhesive tape
removal and tail-hanging response tests. The outcome of each rat in
each test was assessed according to objectively measurable variables,
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and a global neuroscore was assigned to each rat. The higher the score
the more severe the neurological impairment. Neuroscore and infarct
volume were signiﬁcantly correlated (Pearson’s, p = 0.0176).
Neuroscore in sham-surgery rats was indistinguishable from that of
undisturbed rats.
2.6. Patients
Serum samples were obtained from a cohort of 33 ischemic stroke
patients that were admitted within 3 h from the onset of symptoms to
the Stroke Unit of the Hospital Universitari Germans Trias i Pujol
(HUGTIP). Samples were obtained at admission, before the TANDEM-1
clinical trial treatment administration (clinicalTrials.gov Identiﬁer
NCT00777140).
2.7. Determination of HTf extravasation during reperfusion in vivo
Human HTf (hHTf) (Sigma-Aldrich) was labeled with NIR ﬂuor-
escent IRDye 800 (NIR-hHTf*) (LI-COR Biosciences) and administered
i.v. (200 µg) at reperfusion onset. One or 2 h after reperfusion onset,
rats were transcardially perfused with heparinised PBS, whole brains
obtained and imaged in an Odyssey Imager System (LI-COR
Biosciences), and images analyzed using ImageJ.
2.8. Western blot (WB)
Fifty µg of total protein from brain or 8 µg of total protein from
cortical neurons in culture were loaded in Precast NuPAGE Midi 10%
Bis-Tris (Life Technologies). MW markers (Magic Mark XP; Life
Technologies) were included in 10% Bis-Tris gels, and actin or tubulin
were used as tissue sample loading controls. For protein extraction
addressed to detect phosphorylated proteins, we used a lysis buﬀer
containing: 20 mM Tris-Cl pH 7.5, 137 mM NaCl, 1% Nonidet P-40,
0.5% sodium deoxycholate, 100 mM phenylmethylsulfonyl ﬂuoride and
Complete™ EDTA-free Protease Inhibitor Cocktail supplemented with
2 mM EDTA, 5 mM sodium orthovanadate and 50 mM sodium ﬂuoride.
Also, 0.26 µl of either human or rat serum, or 6 µl of cell-conditioned
medium were loaded in Precast 6% TBE urea gels (U-PAGE) (Life
Technologies). Human ATf (hATf) and hHTf from Sigma-Aldrich, and
rat ATf (rATf) and rat HTf (rHTf) prepared in-lab from a commercial rat
Tf (rTf) (Cusabio), were used as electrophoretic standards in U-PAGE.
Rat ATf and rHTf were prepared following previously described pro-
tocols [27,28]. Gels were electroblotted onto PVDF-LF membranes
(Millipore) which were incubated overnight at 4 °C with the speciﬁc
primary antibodies and thereafter with the NIR-conjugated secondary
antibodies. In WB of serum samples of rats administered with hTf, the
human Tf forms (shown in red, using anti-human Tf antibody and read
at 700 nm) show increased electrophoretic mobility as compared with
the equivalent rat Tf forms (shown in green, using anti-rat Tf antibody
and read at 800 nm). Bands were measured using an Odyssey imaging
system and its dedicated software.
2.9. Calculation of TSAT (%)
The method used routinely to calculate TSAT in most reports mea-
sures iron and Tf in serum, but this method is indirect and subject to
misleading results [29]. Direct assessment of transferrin saturation
combining electrophoretic U-PAGE [30] (that separates Tf into ATf
(devoid of iron), two monoferric Tf, and the diferric Tf bands) with
band quantiﬁcation has been reported to be more accurate and reliable
to determine TSAT [29,31,32].
In rats receiving hTf, % TSAT arises from the mixture of all iron-free
and iron-loaded forms of both the endogenous rTf and the exogenous
hTf. Antibodies used were selected to avoid cross-reactivity between
species and to equally recognize ATf and iron-containing Tf forms in
WB.
We calculated % TSAT in serum samples of stroke patients or rats
using our U-PAGE/WB results, according to the formula previously used
by diﬀerent groups [31,33]:
= + + +TSAT(%) (½*mFe·Tf diFe·Tf)*100/ (ATf mFe·Tf diFe·Tf)
2.10. Primary culture of cortical neurons
Cell cultures of rat cortical neurons were prepared as previously
described [34] from male and female E18 fetuses from pregnant
Sprague-Dawley rats (Envigo/Harlan). Neuronal cultures were grown in
Neurobasal™ medium supplemented with 2% B-27 (Life Technologies)
in oxygen and glucose deprivation (OGD) experiments or with 2% NS21
in NMDA-experiments (NS21 supplement was made in-lab to control
the amount of Tf and the TSAT in the culture medium, according to ref.
[35]. All experiments were performed at 12 DIV. Ninety seven % of
cells in cultures were neurons. Independent experiments were per-
formed using neurons obtained from fetuses from diﬀerent pregnant
rats and done on diﬀerent days. Each experimental condition was tested
in at least 3 independent experiments or biological replicates, each with
3–4 technical replicates (culture plate wells).
2.11. Determination of total intracellular ROS, Fe2+ and 4-
hydroxynonenal (4-HNE)
OGD-exposed neurons were reperfused for 30 min in the presence or
the absence of either HTf or FeCl3 in medium containing 5-chlor-
omethyl-2,7-dichlorodihydroﬂuorescein diacetate (CM-H2DCFDA
(Invitrogen, Barcelona, Spain) (10 μM), washed to remove excess dye,
and ﬂuorescence was measured. DCFH-DA easily crosses the membrane
of cells in culture. Once in the cytosol, DCFH-DA is cleaved and be-
comes membrane-impermeable and, when oxidized, it turns into a DCF
ﬂuorophore whose emission brightness has been considered to measure
the levels of cellular ROS. In some conditions, this might not measure
ROS only, but rather detect radicals to which peroxides are converted
by transition metal ions [36]. Therefore, DCFH-DA indeed seems
especially suited to study the eﬀect of iron released from iron-loaded
transferrin on ROS formation during OGD or NMDA-induced ex-
citotoxicity in our study. Fe2+ was assessed with the turn-on FeR-
hoNox™−1 ﬂuorescent probe as described by Hirayama et al. [37] and
obtained from Goryo Chemical Inc. (Goryo, Japan). Five μM FeR-
hoNox™−1 was added to the neuronal medium, incubated for 30 min
in the presence of the treatments and imaged as speciﬁed by the
manufacturer. 4-HNE was determined by immunocytochemistry in
neurons exposed to treatments for 40 min. Images were taken using a
ﬂuorescence AxioObserver Z1 microscope (Carl Zeiss, Germany).
2.12. Neuronal viability assessment
Cell death was determined measuring the incorporation of propi-
dium iodide (PI). We used a Varioskan ﬂash reader (ThermoFisher
Scientiﬁc, Finland) and followed the method by Rudolph and col [38]
adapted in our lab [39].
2.13. OGD
The conditioned medium of 12-DIV neuron cultures was removed
and saved. Neurons exposed to OGD were incubated in glucose-free
DMEM in a 0.2% O2 atmosphere in a Galaxy R+ hypoxia incubator
(RSBiotech). Control cells were incubated in DMEM supplemented with
4.5 g/L glucose at normoxia. After a 90-min period incubation, cultures
were returned to their conditioned medium and further incubated in
normoxic conditions.
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2.14. Immunocytochemistry
Neurons grown on poly-L-lysine-coated glass coverslips were ﬁxed at
4 °C in 4% paraformaldehyde in PBS-2% sucrose, permeabilized in
100% methanol, blocked, and incubated overnight at 4 °C with the
primary antibodies. Subsequently, the cultures were washed, incubated
with secondary antibodies and mounted with Fluoromount (Sigma-
Aldrich) or ProLong® Gold (Life Technologies). Images were generated
on an AxioObserver Z1 microscope (Carl Zeiss), and obtained using an
immersion oil 40x lens (N.A 1.3), a MCR5 camera and Zen Blue soft-
ware (Carl Zeiss). For each treatment, 45 ﬁelds were analyzed (5 ﬁelds/
well, 3 wells/treatment, 3 experiments). Quantiﬁcation was performed
by two researchers blind to the treatments.
To address the cellular localization of hHTf, plasma membrane was
stained with wheat germ agglutinin (WGA) Alexa Fluor® 488 conjugate
(Life Technologies). Neurons were imaged on a confocal microscope
(LSM710; Carl-Zeiss), using an immersion oil 63x lens (N.A. 1.4), a
MCR5 camera and Zen Black software (Carl Zeiss).
Fig. 1. Experimental stroke increases HTf extravasation into ischemic tissue and HTf increases OGD-induced neuronal death. (A) Representative TTC-stained brain slices of a rat exposed
to tMCAO (ligature) plus 24 h reperfusion; scale bar, 1 cm. (B) Representative WB showing Tf and tubulin bands in the ischemic area (Ipsi) at 2 h postreperfusion and in a mirror area in
the contralateral cortex (Contra) or in Control rats (Left and Right). (C) Transferrin/Tubulin ratio from WB bands as in (B) (n = 4 per group; paired t-test: *p = 0.0451). (D) WB NIR-
hHTf*. Representative (E) raw ﬂuorescence and (F) heat-map images of the brain of a rat exposed to tMCAO, injected i.v. with NIR-hHTf* and allowed to reperfuse for 2 h. (G)
Quantiﬁcation of the NIR-hHTf* ﬂuorescence in the hemispheres after tMCAO/2 h reperfusion (n = 6; paired t-test: **p = 0.0072). Representative histological mouse brain slice images
obtained using (H) cresyl violet or (I) immunohistoﬂuorescence for NeuN (green), Tf (red) and nuclei (blue). Brains were obtained from mice exposed to thromboembolic stroke plus 24 h
reperfusion. (J-K) show magniﬁed images; scale bars, 100 µm (in J) and 20 µm (in K).
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2.15. Immunohistochemistry
Fifteen μm slices from cryopreserved optimal cutting temperature
(OCT)-embedded paraformaldehyde-ﬁxed mice brains were obtained
and collected onto poly-L-lysine-coated glass slides, exposed to antigen
retrieval (95-99º C in 0.01 mol/L citrate buﬀer, pH 6.0, for 20 min), and
incubated overnight with the primary antibodies at 4 °C and then with
secondary antibodies and mounted with Fluoromount (Sigma-Aldrich
F4680). Images were obtained using a ﬂuorescence AxioObserver Z1
microscope (Carl Zeiss, Germany).
2.16. Determination of serum Tf levels
Tf levels in the serum of stroke patients and rats were determined by
ELISA (Abnova; Abcam).
2.17. Neuronal uptake of hHTf in three conditions: in the presence of hATf,
after speciﬁc blockade of TfR, and/or after Tf depletion from the
conditioned medium (CM)
Neuronal uptake of hHTf was tracked by incubation with hHTf la-
beled with ﬂuorophore Dyomics 547 (60 nM) (hHTf*; Exbio). We used
hATf at concentrations suitable to compete with hHTf for their common
receptor at the neuronal membrane. An anti-rat TfR monoclonal anti-
body (OX26, 13–26 µg/ml) was used to block the TfR. To deplete Tf
from CM, two sequential immunoprecipitations were performed using
the Dynabeads kit (Invitrogen) and a 1:1 mixture of two monoclonal
antibodies against human Tf (HTF-14 and OT1 clones, Acris
Antibodies).
Cultures were incubated in CM containing either hATf, OX26, and/
or in CM depleted of Tf, before the addition of 50 µM NMDA. Fifteen
min later the cultures were ﬁxed and processed for im-
munocytochemistry to assess hHTf* uptake.
2.18. Antibodies
The following primary antibodies were used for im-
munocytochemistry or WB: rabbit anti-rat Tf polyclonal antibody (4 µg/
ml, Cappel 55720), mouse anti-hTf monoclonal antibodies OT-1 and
HTF-14 (5 µg/ml, Acris Antibodies BM2704 and BM745S, respectively),
mouse anti-tubulin (0.25 µg/ml, Sigma-Aldrich T6074), rabbit anti-
actin (0.25 µg/ml, Sigma-Aldrich A2066), rabbit anti-4-hydro-
xynonenal (4-HNE) (1:750, Enzo Life Sciences ALX-210–767-R100),
goat anti-NRAMP 2, also known as divalent metal transporter 1 (DMT-
1) (1:50, Santa Cruz Biotechnology SC-16887), rabbit anti-death-asso-
ciated protein kinase 1 (DAPK1) polyclonal antibody (2 μg/ml, Sigma-
Aldrich D1319), mouse anti-phospho DAPK1 (pSer308) monoclonal
antibody DPKS308 (20 μg/ml, Sigma-Aldrich D4941). For im-
munohistochemistry, goat anti-mouse Tf polyclonal antibody (20 µg/
ml, Novus Biologicals NB110-82403), rabbit anti-mouse NeuN mono-
clonal 27-4 antibody (1:100, Millipore MABN140) and mouse anti-rat
TfR monoclonal antibody OX-26 (4 µg/ml, Santa Cruz Biotechnology
SC-53059) were used. To block TfR we used the OX26 antibody. The
secondary antibodies IRDye-680 donkey anti-mouse (926–68072) and
IRDye-800 donkey anti-rabbit (926–32213) (1:15,000, LI-COR
Bioscience) were used.
2.19. Statistics
Results are expressed as the mean± SEM. Statistical analyses were
performed using GraphPad Prism. Data were analyzed using unpaired
or paired Student’s t-test, or one-way ANOVA for independent or re-
peated measures followed by the post-hoc Student-Newman-Keuls
multiple comparisons test (SNK), or Mann-Whitney U test, as required.
When necessary, data were log-transformed to achieve homogeneity of
variances. Pearson’s correlation was used when required. The eﬀects
were considered statistically signiﬁcant at p< 0.05.
2.20. Study approval
All the experimental protocols involving rats were approved by the
Institutional Animal Care and Animal Experimentation Committees of
the Centers involved, in compliance with EU directives 86/609/CEE
and 2003/65/CE and conducted in conformity with international
guidelines (Guide for the Care and Use of Laboratory Animals, National
Institutes of Health publication 85-23, 1985), laws and policies. The
TANDEM-1 clinical trial (clinicalTrials.gov Identiﬁer NCT00777140)
had the approval of the Ethical Committee of Clinical Research (CEIC)
of the HUGTIP and the informed consent of all patients.
3. Results
3.1. HTf extravasates and accumulates in neurons of postischemic brain
areas in experimental stroke models
In a model of tMCAO by ligature that reproducibly damages the
same cortical areas 24 h after the ischemia (Fig. 1A), the Tf signal was
27-fold higher in the ipsilateral postischemic than in the contralateral
area, measured 2 h after reperfusion onset (Fig. 1B-C).
To determine whether this Tf increase in the brain resulted from
extravasation or from local Tf expression, near-infrared (NIR)-labeled
hHTf (NIR-hHTf*) (Fig. 1D) was injected i.v. in the rat at reperfusion
onset in an intraluminal tMCAO stroke model; this model avoids un-
speciﬁc NIR signal interference in the brain due to blood leakage at the
site of surgery (neck). Two hours after reperfusion onset, we observed a
30-fold increase in the NIR-hHTf* signal in the ipsilateral vs the con-
tralateral brain hemisphere (Fig. 1E–G).
In addition, we found increased Tf immunostaining in neurons of
the postischemic brain areas 24 h after the MCAO onset in a mouse
model of thromboembolic stroke and reperfusion. Tf signal was in-
creased in the areas identiﬁed as infarct or peri-infarct using cresyl
violet staining; Tf and NeuN colocalized in the same cells, indicating
accumulation of Tf in neuronal bodies (Fig. 1H–K).
3.2. HTf is harmful to neurons exposed to an in vitro model of ischemia
Using an in vitro model of ischemia by OGD, we observed that
neither OGD (90-min plus 30-min reoxygenation) nor hHTf in control
normoxic conditions induced early neuronal death (Fig. 2A). However,
OGD did induce early neuronal death in the presence of hHTf (Fig. 2A).
Importantly, we show that 5 μM exogenous hHTf increased the OGD-
induced DCF emission, which is considered an index of ROS production,
in neurons, whereas 50 μM free iron added to the media did not
(Fig. 2B).
To our knowledge, reports showing toxicity of iron on neurons in
culture have seldom, if ever, considered that Tf, an essential ingredient
of most culture media, might eventually become HTf in the presence of
iron. We found that free iron added to the medium incorporated into Tf
present in the B27-supplemented-medium and increased the intensity of
the band corresponding to diferric Tf (diFe-Tf) (Fig. 2C). Moreover,
Fe3+, that incorporated more eﬃciently than Fe2+ into medium Tf (see
arrows in Fig. 2C), induced early cell death in OGD-exposed neurons at
a lower concentration (20 μM Fe3+) than Fe2+ (Fig. 2D). In addition,
HTf induced cell death at a much lower concentration than free iron
(Figs. 2A and 2D).
OGD did not increase the neuronal levels of TfR (Fig. 2E) but dou-
bled DMT-1 levels (Fig. 2F).
N. DeGregorio-Rocasolano et al. Redox Biology 15 (2018) 143–158
147
Fig. 2. HTf increases OGD-induced ROS production and neuronal death. Neuronal cultures were incubated in OGD or control conditions, while their original conditioned medium was
kept in twin cell-free plates with hHTf, Fe2+ or Fe3+. (A) After OGD, neurons were returned to normoxia in their own original medium, now containing hHTf, and the eﬀect of hHTf in
neuronal death was measured 30 min later (4 independent experiments,≥ 3 wells/group/experiment; one-way ANOVA: p = 0.0014, and SNK test: *p<0.05). (B) Representative images
and quantiﬁcation of free radical production induced by iron or HTf added during reperfusion to neurons previously exposed to OGD (3 independent experiments, ≥ 3 wells/group/
experiment; one-way ANOVA: p<0.05, and SNK test: *p< 0.05 vs neurons exposed to OGD without additional treatment). Scale bar; 100 µm. (C) Representative U-PAGE/WB showing
the bands of ATf, mFe-Tf and diFe-Tf as present in the cell-free culture medium incubated with vehicle, 20 μM Fe2+ or 20 μM Fe3+ for 90 min. Transferrin present in the media was that
included by the commercial supplier in the standard formulation of B-27-supplemented medium. (D) Eﬀect of Fe2+ and Fe3+ on neuronal death in OGD-exposed cultures as measured
30 min after the onset of reoxygenation (3 independent experiments, ≥ 3 wells/group/experiment; one-way ANOVA: p = 0.0027 for Fe2+ and p = 0.0002 for Fe3+, and SNK test:
*p<0.05, **p< 0.01, ***p< 0.001). (E-F) Eﬀect of 90 min OGD on the levels of (E) TfR and (F) DMT-1 as assessed by immunocytochemistry (3 independent experiments,≥ 3 wells/
group/experiment; Mann-Whitney U test: *p = 0.028).
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3.3. Top and bottom TSAT values observed in serum from stroke patients
can be reproduced in the rat by the administration of HTf or ATf,
respectively
We ﬁrst determined TSAT in the serum collected from stroke pa-
tients at admission, by a direct method using U-PAGE/WB that sepa-
rates bands, each band corresponding to diﬀerent human transferrins
with regard to their iron cargo (Fig. 3A). Mean TSAT values in stroke
patients samples was 31.2±1.9%, showing large individual diﬀerences
with values ranging from 13% to 64% (Fig. 3A–B); serum Tf
concentration did not correlate with TSAT (r2 = 0.011, p = 0.553)
(Fig. 3C–D).
Next, to reproduce the top and bottom blood TSAT observed in these
patients, rats received, respectively, hHTf or hATf i.v., and the new
TSAT was calculated (Fig. 3E-F). Baseline TSAT was 44.0±1.9% in
undisturbed rats (Fig. 3G), similarly to sham-operated rats (not shown),
and higher than the average TSAT in stroke patients. Administration of
250 mg/Kg hHTf i.v. to rats increased TSAT to 63.9±2.4% within
minutes and remained increased 1, but not 24, h later. Conversely, i.v.
administration of 300 mg/Kg hATf decreased TSAT to 16.9±1.6%
Fig. 3. Top and bottom blood TSAT measured in stroke patients are reproduced in rats administered HTf or ATf, respectively. (A) U-PAGE/WB showing the electrophoretic pattern of
hATf, C-term and N-term monoferric Tf (mFe-Tf) forms, and diferric Tf (diFe-Tf) form in representative serum samples of stroke patients (red lines separate diﬀerent gels). Human ATf and
hHTf standards were loaded in lanes 1 and 2, respectively. TSAT calculated individually for each patient is indicated below each lane. (B) Individual TSAT values and (C) individual Tf
serum levels of 33 stroke patients, obtained at admission, (D) do not correlate. (E-F) Eﬀect of the administration of (E) hHTf or (F) hATf on TSAT in each individual rat. (G) Time-course
of TSAT before and after the administration of hHTf or hATf (n = 3–5 per group; repeated measures one-way ANOVA: p = 0.0186 for hHTf and p<0.0001 for hATf administration, and
SNK test: *p< 0.05, **p<0.01, ***p< 0.001 vs before administration (t =− 1). (H) Representative U-PAGE/WB showing human (red) and rat (green) bands of ATf, mFe-Tf and diFe-
Tf in rat blood before (t =− 1) and after (t = 0 and 24 h) administration of exogenous hHTf or hATf. The human Tf forms have increased electrophoretic mobility as compared with the
equivalent rat Tf forms (e.g. note that human ATf and rat monoferric transferrin show similar electrophoretic mobility).
N. DeGregorio-Rocasolano et al. Redox Biology 15 (2018) 143–158
149
within minutes, and remained signiﬁcantly below pre-administration
levels 1 and 24 h later (Fig. 3G).
Iron isoforms of rat and human Tf have diﬀerent electrophoretic
mobility (Fig. 3H). Levels of exogenous Tf, administered either as hATf
or hHTf, remained steady in blood during the ﬁrst hour post-adminis-
tration. Exogenous hATf not cleared from rat circulation after a 24-h
period mainly remained in its iron-free form (Figs. 3H and 7A), whereas
exogenous hHTf lost all its iron and converted to hATf after a 24-h
period (Fig. 3H).
3.4. High TSAT increases infarct volume and mortality in rats exposed to
tMCAO
Using the set up conditions shown in experiments in Fig. 3, we next
increased rats’ TSAT up to 64% (High TSAT group, which mimics top
TSAT values in stroke patients) by the administration of hHTf (250 mg/
Kg) or maintained baseline TSAT before they received intraluminal
tMCAO (90 min). A magnetic resonance imaging (MRI) study was car-
ried out to get the time-course evolution of hypoperfused or infarcted
areas in the brain. TSAT still remained increased at the end of the MRI
acquisition period (3 h). No diﬀerences were found in the volume of
brain tissue showing hypoperfusion in MRI perfusion-weighted imaging
(PWI) between vehicle and hHTf-treated rats (approximately 270 mm3
of brain showed hypoperfusion during the occlusion period, Fig. 4A).
Higher diﬀusion-weighted imaging (DWI) volume was found in hHTf-
treated rats when compared with vehicle-treated rats, starting 35 min
after the occlusion (Fig. 4B–C). Brain tissue with reduced blood perfu-
sion (PWI volume) but not included in the lesion core (DWI volume)
indicates penumbral potentially salvageable tissue, according to the
PWI-DWI mismatch concept [40]. We found that, 70 min after re-
perfusion onset, vehicle- and hHTf-treated tMCAO rats had
188.0±46.3 mm3 and 33.3± 35.3 mm3 of salvageable tissue, respec-
tively (Fig. 4D). This indicates that High TSAT rats have almost no
salvageable tissue assessed 70 min after reperfusion (160 min post
MCAO), whereas approximately 70% of the brain volume at risk is still
salvageable in the animals in the vehicle group. Moreover, mortality
during the ﬁrst 24 h following tMCAO in the High TSAT group was 50%
whereas in the vehicle group was 23%, being the later the mortality
usually associated to this stroke model.
3.5. Lowering TSAT at reperfusion reduces infarct volume in rats exposed to
tMCAO
Since intraluminal tMCAO rats with normal baseline TSAT levels
Fig. 4. Experimentally-induced High TSAT with hHTf increases brain damage volume in rats exposed to tMCAO. (A) Representative MRI-PWI coronal sections of rat brains 70 min after
ischemia onset (tMCAO by intraluminal thread) in Veh-treated (left) and hHTf-treated rats (middle). Time-course eﬀect of hHTf-High TSAT on hypoperfused-PWI brain volume during
ischemia and early reperfusion (right) (n = 8–12 per group). (B) Representative ADC maps obtained from DWI of coronal rat brain sections of tMCAO rats (Vehicle, top; hHTf-treated,
bottom) 160 min after the ischemia onset. (C) Time-course eﬀect of hHTf-High TSAT on lesion-DWI volumes during ischemia and early reperfusion (n = 8–12 per group; t-test: *p< 0.05,
#p = 0.0563 vs respective Veh). (D) Salvageable hypoperfused brain tissue as assessed by PWI-DWI mismatch 160 min after the ischemia onset in normal TSAT (Veh) and High TSAT
(hHTf) rats (n = 8–12 per group; t-test: *p = 0.0216).
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still have a large area of salvageable brain tissue at postreperfusion
(Fig. 4D), we next reduced TSAT to 17% by hATf administration at
reperfusion in the Low TSAT-17 group and found a 50% reduction in
the infarct volume 24 h later (Fig. 5A). The protection was larger in the
cortex than in the subcortical area (Fig. 5B).
We then reduced TSAT to 25% (Low TSAT-25) at reperfusion in a
model of tMCAO by ligature, known to aﬀect speciﬁcally cortical areas
only, and obtained a larger protective eﬀect 24 h later (Fig. 5C–D).
3.6. Lowering TSAT reduces brain damage and ameliorates neurological
outcome in an experimental model of pMCAO
Since High TSAT-induced damage begins before reperfusion onset
(DWI-MRI data above), we hypothesized that reduction of TSAT might
be therapeutic without recanalization. To test this, we reduced TSAT
(Fig. 6A–B) (Low TSAT) 1 h after the onset of pMCAO by ligature, and
found a 60% reduction of the infarct volume (Fig. 6C–D) and also of the
neurological deﬁcit (neuroscore) 24 h later (Fig. 6E). Also, TSAT mea-
sured right after hATf administration showed a positive correlation
with the infarct volume (Fig. 6F) and also the neuroscore (Fig. 6G), as
assessed at 24 h. Moreover, ATf therapy reduced pMCAO-induced body
weight loss (Fig. 6H).
3.7. ATf treatment does not block the MCAO-induced extravasation of HTf
Human ATf given to pMCAO rats 1 h following the occlusion and
not cleared from circulation remains in blood as hATf 24 h later
(Fig. 7A), indicating that protection by hATf is unrelated to its iron-
binding capacity in blood. To determine whether hATf therapy might
block the TfR-mediated HTf transport through the blood brain barrier
(BBB) during stroke, rats received vehicle or hATf i.v. (300 mg/Kg) at
reperfusion onset together with exogenous NIR-labeled hHTF (NIR-
hHTf*,< 0.4% of the endogenous blood Tf levels). Exogenous NIR-
hHTf* was determined in brain hemispheres while still largely satu-
rated in blood, 1 h after administration (Fig. 7B). One hour after re-
perfusion, NIR-hHTf* signal was> 50% higher in the ipsilateral-is-
chemic brain hemisphere than in the contralateral one, regardless rats
had been treated or not with hATf (Fig. 7C). Therefore, ATf does not
prevent MCAO-induced NIR-hHTf* uptake in the postischemic brain
hemisphere. Also, the ipsilateral brain hemisphere accumulated 3.7-
fold more exogenous hATf than the contralateral hemisphere 1 h
postreperfusion (Fig. 7D–E).
3.8. Protection by a direct action of ATf at the neuronal level: ATf prevents
NMDA-mediated HTf uptake by neurons and subsequent neuronal death
As expected, blockade of NMDA receptors (NMDAR) with MK-801
fully protected against OGD-induced neuronal death (Fig. 8A). Also,
NMDA in vitro drives import of iron into neurons which is due, at least
partially, to uptake of Tf-bound iron pool (ref. [20] and Figs. 8B and
9B). Within this framework, and since protection by ATf is not due to a
blockade in the extravasation of Tf, we next studied whether ATf
competes with HTf at the neuronal level. Human ATf (≥ 12 μM) pre-
vented the NMDA-induced increase in neuronal uptake of hHTf*
(Fig. 8B–C); most hHTf* incorporated was located in the cytoplasm
(Fig. 8C). In neurons exposed to NMDA, addition of 0.1 μM hHTf to the
Fig. 5. Experimentally-induced Low TSAT at reperfusion reduces
the infarct volume in tMCAO rats. (A) Eﬀect of reduction of TSAT
to 17% (Low TSAT-17) by the administration of 300 mg/Kg hATf
i.v. at reperfusion on the infarct volume (TTC staining) of tMCAO
rats (intraluminal ﬁlament model); scale bar, 1 cm (n = 6–7 per
group; t-test: *p = 0.0103). Representative TTC-stained brain
slices are shown on top of each bar. (B) Eﬀect of Low TSAT-17 on
% infarct volume in cortical and subcortical brain regions (n =
6–7 per group; t-test: *p = 0.0436, **p = 0.0133, ***p = 0.0102
vs respective Veh). (C) Representative TTC-stained brain sections
of rats treated at reperfusion with Veh or 200 mg/Kg hATf (Low
TSAT-25), 24 h after tMCAO (ligature model); this model infarcts
only cortical areas; scale bar, 1 cm. (D) Quantiﬁcation of the ef-
fect of treatment with 200 mg/Kg hATf in the tMCAO model in-
dicated in (C) (n = 6–7 per group; t-test: **p = 0.0036).
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medium increased the cytosolic Fe2+ levels as assessed with the turn-on
Fe2+ speciﬁc probe Rhonox-1 (Fig. 8D). This ferrous iron (Fe2+) is
known to be quickly oxidized to ferric iron (Fe3+) by hydrogen per-
oxide, producing hydroxyl radicals that have very high rate constants
for the reaction with cellular molecules (e.g. ROS attack unsaturated
acyl groups leading to formation of the reactive lipid-derived by-pro-
duct 4-HNE, which forms adducts with several proteins that aﬀect their
function). We found that neurons treated with NMDA in the presence of
Fig. 6. TSAT reduction diminishes brain damage and improves
neurological performance in experimental permanent stroke. (A)
Representative U-PAGE/WB showing the ATf, mFe-Tf, and the
diFe-Tf bands of rat Tf (green) and iron forms of human Tf (red) in
serum of two rats treated with hATf (R1+hATf and R2+hATf).
Samples were obtained from undisturbed animals (Pre), 60 min
after ischemia onset and before reducing TSAT (AI), or right after
the administration of hATf (AA). (B) Eﬀect of i.v. hATf adminis-
tration (200 mg/Kg) on the % TSAT (rat+human), calculated as
explained in methods (n = 7–8 per group; t-test: ***p< 0.0001).
(C) Representative TTC-stained brain slices of rats exposed to
pMCAO (ligature) and treated with Veh or hATf 1 h later; slices
were obtained 24 h later; scale bar, 1 cm. Eﬀect of hATf-Low
TSAT on (D) the infarct volume produced by pMCAO at 24 h (n =
8 per group; t-test: *p = 0.0181) and (E) the neurological score (n
= 8 per group; t-test: *p = 0.0354). Signiﬁcant positive corre-
lations between TSAT measured after the administration of hATf
and (F) the infarct size and (G) the neuroscore, both measured
24 h after pMCAO. (H) Eﬀect of Low TSAT on body weight loss
24 h after pMCAO (n = 8 per group; t-test: *p = 0.0251).
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0.065 μM hHTf generate 4-HNE (Fig. 8E), and that this eﬀect was
prevented by hATf. Also, we found a strong neuroprotective, con-
centration-dependent, eﬀect of hATf on NMDA-induced neuronal death
at 4 h (Fig. 8F) and a 40% reduction of the NMDA-induced neuronal
death 24 h later (Fig. 8G).
Moreover, blockade of the HTf uptake with anti-TfR antibody OX26
(Fig. 9A–B), removal of the Tf present in the extracellular medium (see
Fig. 9C), and the sum of Tf removal plus TfR blockade also reduced
NMDA-induced neuronal death at 24 h (Fig. 9D). We also found that the
well-known NMDA-induced Ca2+ inﬂux turns into increased calci-
neurin activity, as measured through a decrease in the pDAPK1/DAPK1
ratio (Fig. 9E–F). Whereas blockade of NMDAR with MK-801 restored
pDAPK1/DAPK1 to control levels, hATf had no eﬀect on this speciﬁc
parameter. None of the treatments aﬀected DAPK1 levels as no changes
were observed in DAPK1/actin ratios.
4. Discussion
Previous studies that associate iron overload conditions with in-
creased brain damage in stroke [6,8,41] have seldom addressed the role
of the iron transport protein transferrin or the role of TSAT.
The present study reveals a prompt accumulation of circulating la-
beled NIR-hHTf* and endogenous rat Tf into the brain areas aﬀected by
the MCAO as early as 1 h after reperfusion onset, gaining extent at 2 h.
In addition, we demonstrate that HTf enhances ROS production and
OGD-induced neuronal death in vitro, even more eﬀectively than free
iron. The ﬁnding that Fe3+ was more eﬃcient than Fe2+ in provoking
neuronal death after ischemia might be attributable to the fact that
Fe2+ has to be previously converted to Fe3+ to bind Tf present in our
B27-supplemented medium. All the above suggests that extracellular
free iron binds Tf (as shown in Fig. 2C) to be incorporated into neurons
through TfR and to become deleterious in OGD conditions. OGD itself
does not change neuronal TfR levels but doubles DMT-1 levels in
neurons. Ischemia/excitotoxicity has been reported to increase en-
docytosis [42]. In such an increased Tf-TfR endocytosis scenario, more
iron-loaded transferrin would gain access to endosomes and more iron
would be released into the acidic endosomal lumen. Thus, increased
DMT-1 transporter levels in the endosomal wall would promote in-
creased iron egress from endosomes into neuronal cytosol.
The stroke-induced HTf extravasation to the brain parenchyma,
together with the damaging eﬀect of HTf on OGD-exposed neurons,
suggests that high TSAT in blood could play a pivotal role in increasing
the damage in stroke. To directly evaluate this issue, we administered
HTf iv to increase TSAT to 64% (High TSAT) and found exacerbated
brain damage in tMCAO rats (ﬁlament thread model; DWI in MRI time-
course experiments). Conversely, administration of ATf iv to reduce
TSAT at the onset of reperfusion (17–25%, Low TSAT) reduced the
infarct volume in the two transient stroke models tested. Importantly,
Fig. 7. Neither ATf iron-binding capacity nor a blockade of Tf
extravasation explain protection by ATf. (A) Representative U-
PAGE/WB images of the human Tf forms present in MCAO rat
serum samples (R1 to R6) obtained right after the administration
of hATf (AA) and 24 h later (A24). (B) Human HTf was ad-
ministered i.v. to rats and TSAT of human Tf was determined in
rat blood at diﬀerent time-points. Human HTf retains most of its
iron within the ﬁrst hour after being administered, but loses most
of the iron 24 h later (n = 4–5 per group; repeated measures one-
way ANOVA: p = 0.0002, and SNK test, *p< 0.05,
***p< 0.001). (C) Quantiﬁcation of NIR ﬂuorescence in brains of
rats exposed to tMCAO and administered NIR-hHTf* (0.8 mg/Kg)
plus either Veh (green) or hATf (300 mg/Kg) (blue) at reperfusion
onset. One hour later, brains were obtained and NIR ﬂuorescence
measured in the contralateral (Co) and the ipsilateral (Ip) hemi-
spheres (n = 4–5 per group; paired t-test: *p = 0.0239 and **p =
0.0050 vs respective Co). (D) After NIR imaging, brains in (C)
were processed and representative WB shows bands corre-
sponding to exogenous hATf and actin, in Co and Ip hemispheres
of Veh and hATf-treated rats 1 h after reperfusion. (E)
Quantiﬁcation of hATf levels in WB of brain hemispheres (n =
4–5 per group; paired t-test: *p = 0.0500).
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serum Tf levels we measured in the experimentally-induced High and
Low TSAT rats doubled those of normal rats (8.67± 0.89, 8.61±0.57
and 4.10± 0.27 mg/ml, respectively), this proving that serum Tf sa-
turation with iron, rather than Tf levels, determines the growth and
extent of stroke damage. This conclusion would not be in line with the
role of blood Tf levels in neuroprotection during stroke suggested by
Altamura and col. [43]; their assumption was based on a signiﬁcant
negative correlation of the National Institutes of Health Stroke Scale
(NIHSS) score at admission and serum Tf levels in samples obtained
within the next 48 h. However, NIHSS score at admission evaluates
transient loss of function and not the ﬁnal extent of stroke damage or
neurological outcome; also, the TSAT was not determined in that study
(Fig. 10).
The DWI-MRI experiment showed that High TSAT-induced damage
Fig. 8. Human ATf prevents NMDA-induced hHTf
uptake by neurons and protects from NMDA-induced
neuronal death. (A) MK-801 (10 µM) added at re-
perfusion abolished OGD-induced neuronal death in
vitro observed 24 h later (5 independent experi-
ments, ≥ 3 wells/group/experiment; t-test:
***p< 0.0001 vs control). (B) Eﬀect of hATf on
neuronal uptake of hHTf* (0.06 μM) in neuron cul-
tures treated with NMDA (50 µM) or vehicle (3 in-
dependent experiments, ≥ 3 wells/group/experi-
ment, 5–6 ﬁelds/well; t-test: $$$ p<0.0001; one-
way ANOVA: p< 0.0001 in both NMDA-treated and
vehicle-treated, and SNK test: +++ and
***p< 0.001). (C) Representative confocal images
of neurons 15 min after being treated with NMDA or
Vehicle in the presence or absence of hATf (24 µM).
Neurons were incubated in the presence of both
hHTf* (red) and membrane-staining ﬂuorescent
WGA (green); nuclei are shown in blue; scale bar,
10 µm. (D) Eﬀect of hHTf on the ﬂuorescence turn-
on of the Fe2+ speciﬁc ﬂuorescent probe Rhonox-1
in neurons exposed to NMDA (50 µM) (5 in-
dependent experiments, ≥ 3 wells/group/experi-
ment, 5–6 ﬁelds/well; t-test: p are indicated in the
graph). (E) Eﬀect of hATf on 50 µM NMDA-induced
4-HNE production (3 independent experiments, ≥ 3
wells/group/experiment, 5–6 ﬁelds/well; t-test:
***p< 0.0001, * p = 0.0137). (F-G) Eﬀect of hATf
on neuronal death in neurons exposed to NMDA
(50 µM) for (F) 4 or (G) 24 h (3 independent ex-
periments, ≥ 3 wells/group/experiment; t-test: $$$
p = 0.0010; one-way ANOVA: p = 0.0040, and SNK
test: *p< 0.05, **p< 0.01, ***p<0.001 vs NMDA-
0 µM hATf).
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begins before reperfusion onset, and suggests that TfR-mediated brain
uptake of transferrin molecules occurs during occlusion as reported
previously for TfR-speciﬁc antibodies in conditions of severe blood ﬂow
reduction [44]. Consistent with this, we found that a reduction of TSAT
from the baseline (44%) to 22% 1 h after the onset of pMCAO limited
the infarct size (65% protection), the weight loss, and the neurological
deﬁcit 24 h later in this model. Also, TSAT measured right after ATf
administration correlated with the 24-h infarct volume and with the
neuroscore despite they received the treatment 1 h after stroke onset
and did not recanalize afterwards. Remarkably, from a translational
point of view, our results might be clinically relevant considering the
relative large individual diﬀerences in the TSAT we determined in 33
stroke patients at admission; such diﬀerences have also been observed
in non-stroke human cohorts [10–12]. To our knowledge, there is only
one (epidemiological) report, the NHANES I study, addressing a similar
issue and from a diﬀerent point of view. This report used retrospective
TSAT determinations (made even years before the stroke event) esti-
mated by an indirect method (serum iron/total iron-binding capacity).
The authors said they found an inconsistent U-shaped association be-
tween TSAT and stroke death only in Caucasian women [45].
Since the endogenous iron-binding capacity of blood Tf exceeds by
far the physiological needs, it is unlikely that exogenous hATf ad-
ministered might exert protection by means of a classical chelation
eﬀect in serum (binding, sequestering and excretion of iron, as done by
classical chelators such as deferoxamine). This was actually proved by
the fact that exogenous hATf administered to rats does not generate
Fig. 9. Blockade of TfR and/or removal of extra-
cellular Tf reduce NMDA-induced neuronal death.
(A) Images show the eﬀect of blockade of TfR
(OX26) on the NMDA-induced neuronal incorpora-
tion of hHTf* (0.06 μM); scale bar, 20 µm. Neurons
were treated with NMDA (50 μM). (B) Quantiﬁcation
of the eﬀect depicted in (A) (3 independent experi-
ments, 3 wells/group/experiment, 5 ﬁelds/well; t-
test: +++ p<0.0001; one-way ANOVA: p =
0.0021, and SNK test: * p< 0.05, ** p< 0.01). (C)
SDS-PAGE/WB shows Tf depletion (dep) from con-
ditioned medium (CM) after two (1st and 2nd) con-
secutive rounds of immunoprecipitation. (D)
Blockade of TfR (OX26), incubation in Tf depleted
medium (Tf dep) or both reduce NMDA-induced
neuronal death at 24 h (3 independent experiments,
≥ 3 wells/group/experiment; t-test, *p = 0.0152,
***p< 0.0001). (E) Representative WB showing
pDAPK1, DAPK1 and actin bands obtained from
neurons exposed for 40 min to the treatments in-
dicated, and (F) quantiﬁcation of pDAK1/DAPK1
ratio from WB as in (E) (3 independent experiments,
≥ 3 wells/group/experiment; t-test: * p = 0.0114
and + p = 0.0169).
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iron-bound species of human Tf in rat serum either at 1 h (not shown)
or 24 h later. The therapeutic eﬃcacy of the administration of ATf (Low
TSAT) we report here was not observed in a previous report in which
authors used a lower ATf dose in a model of global ischemia by cir-
culatory arrest in pigs, and in which TSAT was not determined [46].
However, a circulatory arrest, in contrast with focal stroke models we
have used, produces global brain ischemia. In addition, the iron con-
dition of pigs in Heikkinen et al’s report is unknown and in heavy iron-
overload conditions apotransferrin might eventually bind iron, thus
losing its protective potential.
However, in patients exposed to myeloablative conditions, Sahlstedt
and col. showed that, even in extremely high blood iron overload
(myeloablation results in a TSAT between 87–94%, close to full occu-
pation of transferrin iron sites and having additional free iron in blood),
the administration of a dose of ATf half the lowest we used in our report
induced a signiﬁcant reduction of TSAT: a single ATf administration
decreased TSAT from 91% down to 30–49% 2 h later, and half the
patients still showed reduced TSAT (60%) 12 h after the treatment [47].
Therefore, in the expected conditions of stroke patients at admission, 1/
using an ATf dose higher than that used by Sahlstedt, and 2/ with the
stroke patients, even those suﬀering hemochromatosis, facing a less
severe iron overload as compared to patients in Sahlstedt’s report, we
could expect a signiﬁcant eﬀect of the ATf treatment reducing TSAT.
Therefore, since the ﬁrst hours following the stroke event onset are
known to be crucial to determine the stroke infarct development and
the ﬁnal outcome, our ATf treatment approach might represent an ef-
fective therapeutic opportunity for stroke patients given the safety re-
cord of ATf in humans [47].
With regard to the physiological mechanism involved in neuropro-
tection by ATf, our results in vivo indicate that protection by ATf is not
related to a blockade in the extravasation of HTf. However, in neurons
cultured in medium containing Tf at the saturation and concentration
within the range of cerebrospinal ﬂuid Tf [48–50], ATf completely
prevented both the NMDA-induced HTf uptake and the early NMDA-
induced neuronal death (Fig. 8). The concentrations of ATf required to
prevent NMDA-induced neurodegeneration ﬁt with a competitive eﬀect
at the level of TfR, according to the reported aﬃnity of HTf and ATf for
its common receptor [18].
Ischemic-reperfused neurons are known to be exposed to NMDAR-
mediated oxidative stress. In our hands, in accordance with the report
by Lim and col. [51], OGD increased the lipid peroxidation product 4-
HNE early after reperfusion [52]. In addition, we report here that an
activation of NMDAR, known to mediate OGD-induced cell death,
produces: 1/ NMDA induced HTf uptake, 2/ an increase of the cytosolic
pool of labile Fe2+ as assessed by measuring Rhonox-1 ﬂuorescence in
the presence of added 0.1 µM hHTf, and 3/ an excess of lipid-derived
product 4-HNE induced by NMDA in neurons on medium containing
0.065 µM HTf that was prevented in the presence of competing con-
centrations of ATf. Thus, the NMDA-induced neuronal uptake of iron
loaded-transferrin increases neuronal ROS production and neuronal
death. Conversely, blockade of transferrin receptors or removal of ex-
tracellular transferrin reduced cell death initiated by NMDAR over-
activation to an extent similar to that exerted by ATf; this indicates the
pivotal role of HTf and TfRs in mediating, at least partially, ischemic
cell death. The dual involvement of excess ROS/lipid peroxidation and
the requirement of transferrin-TfR-mediated iron uptake we observed in
the present study has also been reported as key features in some fer-
roptosis models [53,54], thus suggesting that at least part of the is-
chemic neurons may degenerate undergoing a form of ferroptosis. The
study of this possibility goes beyond the objective of the present work
but deserves attention, especially considering the protective role of
apotransferrin in experimental ischemic stroke.
The classical transferrin-TfR-mediated endocytosis model [14,55]
describes that HTf-TfR is internalized in endosomes, and establishes
that, whereas endosome free iron is released into cytosol, ATf is not;
instead the endosomal ATf-TfR complex returns to the cell membrane.
Fig. 10. Schematic representation showing that holotransferrin promotes and apotransferrin prevents a form of oxidative, iron- and NMDAR-dependent neuronal death in experimental
stroke. The diagram highlights the key role of blood TSAT on neuronal fate in brain ischemic tissue in rat models of stroke, as increasing TSAT with HTf results detrimental whereas
decreasing TSAT with ATf is therapeutic.
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Also, the presence of some ATf molecules in the cytosol of ischemic
neurons that might bind residual intracellular free iron is unlikely and
has not been supported by experimental evidence to date; this role
(cytosolic free iron binding) is assumed by the molecule ferritin.
It is well known that following NMDAR activation, Ca2+ inﬂux in-
creases the activity of neuronal calcineurin which, in turn, depho-
sphorylates its downstream target DAPK1 [56]. Also, our results show
that ATf, that reduced the Tf/TfR-mediated ROS-4-HNE production
pathway but did not aﬀect the Ca2 +-mediated DAPK1 signaling
pathway, was able to reduce neuronal death. Therefore, our results
indicate that these two pathways initiated by NMDAR overactivation
contribute, in an additive mode, to neuronal death and that ATf is able
to reduce neuronal death without targeting NMDA receptor canonical
signaling.
In summary, we show that holotransferrin promotes and apo-
transferrin prevents a form of oxidative, iron- and NMDAR-initiated
neuronal death in experimental stroke. Our results highlight the key
role of blood TSAT on infarct size and neurological outcome in rat
models of stroke, as increasing TSAT with HTf results detrimental
whereas decreasing TSAT with ATf is therapeutic.
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